|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Matinas Biopharma Holdings, Inc. (MTNB) |
|
|
$0.17 0.00 (0.23%) as of 4:30 Thu 5/16
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
199,250,000 |
| Market
Cap: |
34.47(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1226 - $0.641 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Matinas Biopharma Holdings is a biopharmaceutical company focused on development of its product candidate: MAT9001, a purified, prescription-only omega-3 free fatty acid formulation designed for the treatment of cardiovascular and metabolic conditions; and the application of its lipid nano-crystal (LNC) platform delivery technology to solve challenges relating to the delivery of small molecules, vaccines, proteins and peptides. Co.'s lead drug candidate based on the LNC platform delivery technology is MAT2203, which is an antifungal drug. Co.'s second clinical stage LNC-based product candidate is MAT2501, an orally administered formulation of aminoglycoside antibiotic amikacin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Conrad Herbert J |
Director |
– • – |
2018-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
31,579 |
3,911,179 |
|
- |
|
| Scibetta James S |
Director |
– • – |
2018-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
24,672 |
442,981 |
|
- |
|
| Wikler Matthew |
Director |
– • – |
2018-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
18,422 |
18,422 |
|
- |
|
| Stern Adam K |
Director |
– • – |
2017-12-27 |
4 |
GD |
$0.00 |
$0 |
I/I |
750,000 |
2,939,483 |
|
- |
|
| Stern Adam K |
Director |
– • – |
2017-12-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
750,000 |
1,750,000 |
|
- |
|
| Mannino Raphael J |
Chief Scientific Officer |
• – – |
2017-09-11 |
4 |
B |
$1.41 |
$7,050 |
D/D |
5,000 |
1,424,565 |
2.74 |
- |
|
| Rongen Roelof |
Chief Executive Officer |
• • – |
2017-09-08 |
4 |
B |
$1.36 |
$6,800 |
D/D |
5,000 |
3,539,416 |
2.81 |
- |
|
| Stern Adam K |
Director |
– • – |
2017-09-08 |
4 |
B |
$1.38 |
$69,000 |
I/I |
50,000 |
3,689,483 |
2.1 |
- |
|
| Stern Adam K |
Director |
– • – |
2017-09-07 |
4 |
B |
$1.38 |
$69,000 |
I/I |
50,000 |
3,639,483 |
2.1 |
- |
|
| Ferrari Stefano |
Director |
– • – |
2017-09-07 |
4 |
B |
$1.24 |
$6,200 |
D/D |
5,000 |
203,984 |
2.39 |
- |
|
| Conrad Herbert J |
Director |
– • – |
2017-09-07 |
4 |
B |
$1.30 |
$130,000 |
D/D |
100,000 |
3,879,600 |
2.39 |
- |
|
| Scibetta James S |
Director |
– • – |
2017-09-07 |
4 |
B |
$1.29 |
$6,450 |
D/D |
5,000 |
418,309 |
2.39 |
- |
|
| Gjg Capital, Llc |
Shareholder |
– – – |
2017-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
1,565,333 |
2,086,576 |
|
- |
|
| Gjg Capital, Llc |
Shareholder |
– – – |
2017-06-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,496,760) |
0 |
|
- |
|
| Ende Eric J |
Director |
– • – |
2017-04-03 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,201 |
12,201 |
|
- |
|
| Gjg Capital, Llc |
10% Owner |
– – • |
2017-03-15 |
4 |
OE |
$0.75 |
$1,026,877 |
I/I |
1,369,169 |
10,496,760 |
|
- |
|
| Conrad Herbert J |
Director |
– • – |
2017-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,779,600 |
|
- |
|
| Scibetta James S |
Director |
– • – |
2017-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
413,309 |
|
- |
|
| Mannino Raphael J |
Chief Scientific OfficerOffice |
• – – |
2017-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,419,565 |
|
- |
|
| Stern Adam K |
Director |
– • • |
2017-03-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,789,483 |
|
- |
|
| Stern Adam K |
Director |
– • • |
2017-03-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
793,992 |
|
- |
|
121 Records found
|
|
Page 5 of 5 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
